Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Latest  Sep 23, 2020  3 years, 6 months, 3 weeks, 4 days, 9 hours ago

BREAKING! COVID-19 Latest: University Of Manchester Study Shows That SARS-CoV-2 Mutilates Blood Marrow Cells

BREAKING! COVID-19 Latest: University Of Manchester Study Shows That SARS-CoV-2 Mutilates Blood Marrow Cells
Source: COVID-19 Latest  Sep 23, 2020  3 years, 6 months, 3 weeks, 4 days, 9 hours ago
COVID-19 Latest: Researchers from University of Manchester-UK have made a startling discovery that the SARS-Cov-2 damages blood marrow cells especially the myeloid cells originating from the hematopoietic stem cells of the bone marrow.


 
The study team found that of the myeloid cells damaged by the novel coronavirus, the monocytes are in particular affected.
 
The study results were published in the journal Science Immunology. https://immunology.sciencemag.org/content/5/51/eabd6197
 
Past research have found that COVID-19 creates an "exaggerated" response from the immune system, and for some patients, this could occur in immune cells found in bone marrow, the study team said.
 
The study findings "lend support to the idea that therapeutic strategies targeting release of … cells from bone marrow should be considered in this disease," the team said.
 
The study team carried out the Coronavirus Immune Response and Clinical Outcomes (CIRCO) study at four hospitals in Greater Manchester, UK, which was designed to examine the kinetics of the immune response in COVID-19 patients, as well as to identify early indicators of disease severity. 
 
In total, 73 patients were recruited but only 49 were stratified for maximum disease severity. Six patients were excluded due to: an alternative diagnosis. The overall median age was 61 and 63% were male. The most frequent co-morbidities were diabetes, ischemic heart disease, hypertension, asthma and chronic obstructive pulmonary disease (COPD. Patient disease severity was defined as mild (less than 28% FiO2), moderate (28-60% FiO2) or severe (above 60% FiO2, or admission to intensive care).
 
The British researchers team analyzed the immune profiles of 43 hospitalized patients. They found several shifts in immune signatures, particularly monocytes, which are new immune cells that are released into the bloodstream from bone marrow.
 
By analyzing fresh blood samples immediately without prior storage the study team outlined unappreciated immune abnormalities present within COVID-19 patients. Assessment of inflammatory mediators within the blood demonstrated these immune properties were most dysregulated in patients with severe COVID-19 prior to admission to intensive care, indicating immune modulating therapies should be considered early after admission.
 
Furthermore, the study demonstrated profound alterations in the myeloid cells of COVID-19 patients. The study data demonstrate that monocytes from COVID-19 patients displayed elevated levels of the cell cycle marker Ki-67 but reduced expression of the prostaglandin-generating enzyme COX-2, with both these features being predominant in severe COVID-19 patients. These findings not only identify possible immune biomarkers for patient stratification but potential mechanisms of immune dysfunction contributing to the immunopathology of COVID-19.
 
Interestingly for most patients with mild COVID-19, abnormal levels shifted back to normal during their hospital stay but what this study findings holds in term of long term health implications is not known